跳转至内容
Merck
  • Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons.

Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons.

Journal of Alzheimer's disease : JAD (2019-07-01)
Seokjo Kang, Sung Min Son, Sung Hoon Baik, Jinhee Yang, Inhee Mook-Jung
摘要

Increased levels of total tau (t-tau) and hyperphosphorylated tau (p-tau) proteins in the cerebrospinal fluid of Alzheimer's disease (AD) patients are well documented and strongly correlate with AD pathology. Recent studies have further shown that human tau can be released into the extracellular space and transferred to nascent neurons. However, because the tau protein has no signal peptide identity, the mechanisms underlying its secretion remain poorly understood. In the present study, we confirmed that tau protein secretion was promoted by autophagy inducers and downregulated by beclin1 knockdown or autophagy inhibitors derived from human wild type tau (wt-tau)-overexpressing SH-SY5Y cells. Moreover, both t-tau and p-tau secretion were increased by autophagy activation. Furthermore, we identified that six isoforms of tau protein are secreted in an autophagy-dependent manner. These results indicate that both normal and pathological tau are secreted via an autophagy-mediated secretory pathway in neurons. Understanding this new pathway for tau secretion may provide critical future insights into tau pathologies, such as AD.

材料
货号
品牌
产品描述

Sigma-Aldrich
Triton X-100, for molecular biology
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
D-(+)-海藻糖 二水合物, ≥99% (HPLC), from Saccharomyces cerevisiae
Sigma-Aldrich
巴弗洛霉素A1 来源于灰色链霉菌, ≥90% (HPLC)
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
尼日利亚菌素 钠盐, ≥98% (TLC)
Sigma-Aldrich
三氯乙酸, ACS reagent, ≥99.0%
Sigma-Aldrich
雷帕霉素, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Sigma-Aldrich
3-甲基腺嘌呤, autophagy inhibitor
Sigma-Aldrich
Spautin-1, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human BECN1